Guerbet to present its innovative solution offering for interventional imaging at CIRSE 2019
An innovation lab with 2 dedicated demo rooms for Vectorio® and SeQure®;
SeQure® microcatheter pre-clinical data presentation;
2 symposia in Oncology and Vascular Embolization.
Villepinte (France) – August 29, 2019 - 06:00pm (CEST) - Guerbet (FR0000032526 GBT), a global specialist of contrast agents and other solutions for medical imaging, will present its interventional imaging solutions offering at the CIRSE 2019 (Cardiovascular & Interventional Radiological Society of Europe) in Barcelona, Spain from September 7 to 11 2019 at booth #53 and in its Innovation Lab.
“ CIRSE is the most prominent annual event organized for interventional radiology professionals and we will present our innovative solutions for interventional imaging along with Guerbet’s flagship product Lipiodol® Ultra Fluid in our Innovation Lab with two demo rooms: 1 dedicated to Vectorio® and 1 dedicated to SeQure®, enabling interventional radiologists to discover and test them », said Guerbet Interventional Radiology Commercial VP Thomas Bonnefont. “We are continuing to develop our portfolio with the objective of helping healthcare professionals improve the quality of treatment in image-guided embolization procedures.”
Vectorio® is a Lipiodol® resistant mixing & injection system for conventional Trans-Arterial Chemo-Embolization (cTACE). It’s a unique single use product resistant to Lipiodol® Ultra Fluid up to 24 hours. 4 patent families are concerning specific parts of Vectorio® system. Vectorio® obtained CE labelling in August 2017 and is registered in these followed countries: Austria, Belgium, Brazil, Croatia, France, Hong Kong, Hungary, Luxembourg, Mexico, New Zealand, Peru, Portugal, Czech Republic, South Korea, Switzerland, Thailand, The Netherlands, Turkey, Vietnam.
Guerbet Innovation Lab - Vectorio®
Learn more on cTACE mixture standardization using Vectorio®
From September 7 to 10 - 09:00 - 12:00 and 1:00 - 6:00pm
By Philippe Havard (Global Head of Marketing), Amy Wei (Global Product Manager).
About SeQure® microcatheter:
The SeQure® microcatheter is an innovative reflux control microcatheter It consists of side slits which size has been specifically designed to allow the outflow of contrast media, creating a fluid barrier around the microcatheter to reduce microspheres reflux and assist delivery to the target vessel. SeQure® obtained the CE mark in April 2019. The SeQure® microcatheter received FDA clearance on January 26, 2018 and is commercialized on the US market. It is also registered in Australia, Brazil, Hong Kong, New Zealand, Thailand, Turkey.
Guerbet Innovation Lab - SeQure®
Discover SeQure® Control Reflux microcatheter – Flow dynamics based technology
From September 7 to 10 - 09:00 - 12:00am and 1:00 - 6:00pm
By Eleonora Manca (EMEA Applications Specialist) and Eam-Maly Nam (Global Product Manager).
Reduced nontarget embolization and increased targeted delivery with SeQure®
microcatheter demonstrated in swine model
Pre-clinical study results at scientific session FP 1407 – Experimental studies in IR
On September 8 – 4:15 – 5:15 pm – Room 114
By Prof. Geert Maleux, UZ Leuven, Belgium
Guerbet will also be organizing two symposia:
« Future perspectives in Lipiodol® use for liver diseases management » and « Vascular Embolization: Improved delivery through better flow management » that will take place in Room 117 respectively on Sunday, September 8 from 1 to 2 pm and Monday, September 9 from 11:30 am to 12:30 pm